Navigation Links
Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment
Date:11/25/2013

BETHESDA, Md., Nov. 25, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, has completed an underwritten public offering of 4,895,834 units at a public offering price of $4.80 per unit, resulting in gross proceeds of $23,500,000.  Northwest also announced today that the underwriter has exercised in full its option to purchase an additional 734,374 units to cover over-allotments. Exercise of the over-allotment option increases the gross proceeds to the Company to $27,025,000.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Each unit consists of one share of common stock, and a warrant to purchase 0.5 shares of common stock at an exercise price of $6.00 per share. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.

Oppenheimer & Co. Inc. served as the sole book-running manager for the offering.

The securities described were offered pursuant to a shelf registration statement (File No. 333-185898), which was declared effective by the United States Securities and Exchange Commission ("SEC") on February 5, 2013.  A prospectus supplement and an accompanying prospectus relating to the offering was filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8563, or by email at EquityProspectus@opco.com, or by accessing the SEC's website at www.sec.gov.  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. 

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, including risks related to the Company's use of the offering proceeds, the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
2. Chicago Man Breathes Again Thanks to Northwestern Medicine Study
3. Inaugural Obliteride Sets Northwest Fundraising Record
4. MinuteClinic Signs Clinical Collaboration with Baptist Health Care for Clinic Locations in Three-County Region of Northwest Florida
5. Northwestern Medicine Researchers Investigate New Stent Technology to Treat Coronary Artery Disease
6. Northwest Biotherapeutics Announces Registered Direct Offering
7. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
8. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
9. HealthWarehouse.com and Northwest Physicians Network Partner to Provide Exclusive Discount Pharmacy Services to Patients
10. Northwest Bio Awarded $5.5 Million German Government Grant
11. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... Ore. , Aug. 2, 2017  Life Flight Network ... Agreement. The agreement improves patient care and operational efficiency for ... Springfield , Cottage Grove , ... level medical transportation. PeaceHealth and Life Flight Network work collaboratively ... available during transport, or when a time sensitive emergency exists. ...
(Date:7/31/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one ... by Crain,s Detroit Business . The annual ... three-year revenue growth. This year,s edition measures growth from 2013 ... the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... said Phil Hagerman , CEO and chairman of Diplomat. ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... The digital health ... organization with pending recognition status from the Centers for Disease Control and Prevention ... classes and live video conferencing. , The DPP resulted from clinical work ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician ... its Orlando location as an interventional pain management physician. He brings a wealth ... treatment of migraine headaches, and significant experience in spinal cord stimulation for chronic ...
(Date:8/18/2017)... New York, New York (PRWEB) , ... ... ... Q International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized ... today announced it has entered into a definitive agreement to purchase Unitrans ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
(Date:8/18/2017)... ... , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection and ... Academy in a charity drive to provide for at-risk children and teens in the ... is a nonprofit organization that has offered critical programs to at-risk and foster children ...
Breaking Medicine News(10 mins):